G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/53 (2006.01) C12N 15/12 (2006.01)
Patent
CA 2532534
The expression dose of a histamine-releasing factor (HRF) polynucleotide in a biological sample of a subject is measured and the HRF polynucleotide content is compared with that of a normal biological sample. An HRF polynucleotide expression dose considerably higher than that of the normal biological sample is employed as an indication of a disease relating to endometriosis or a risk thereof.
La dose d'expression d'un polynucléotide de facteur histaminolibérateur (HRF) dans un échantillon biologique d'un sujet est mesurée et la teneur en polynucléotide HRF est comparée à celle d'un échantillon biologique normal. Une dose d'expression de polynucléotide HRF considérablement supérieure à celle de l'échantillon biologique normal est utilisée comme une indication d'une maladie associée à une endométriose ou d'un risque de telle maladie.
Kosugi Yoshinori
Kuroda Masahiko
Ohbayashi Tetsuya
Oikawa Kosuke
Japan Science And Technology Agency
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Methods for diagnosing endometriosis-related diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosing endometriosis-related diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing endometriosis-related diseases will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2078751